Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077751 · ClinicalTrials.gov registry record · Phase 1
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
A Phase 1 study of Anemia, sponsored by John A Widness.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02077751 is a Phase 1 study of Anemia that has completed, run by John A Widness. The registered enrollment target is 3 participants, below the 428-participant average among 72 other Anemia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02077751, a Phase 1 study of Anemia, has completed, sponsored by John A Widness.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: To gather safety and efficacy BioRBC data from adult subjects who previously developed transient BioRBC antibody responses by redosing them and observing for adverse clinical or laboratory (i.e., a positive BioRBC antibody titer) outcomes to determine if RBC kinetic study results differ from the previous study. Hypothesis: BioRBC survival studies performed in adult subjects who previously developed a transient BioRBC antibody response will: 1) be associated with no adverse clinical or laboratory events; 2) experience a second transient, BioRBC antibody response; and 3) display a pattern of RBC survival that is identical to their prior dosing with BioRBCs at the same dose.
Conditions Studied
Interventions
- DRUG biotin labelled RBCs
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077751
The ClinicalTrials.gov registry entry for NCT02077751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 428-participant average among 72 other Anemia trials with a reported enrollment target (99% lower). The listed sponsor is John A Widness, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which biotin labelled RBCs is the first listed.
NCT02077751 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT02077751 about?
NCT02077751 is a clinical study titled "BioRBC Survival in Adults With Prior Antibody Response to BioRBCs". Objective: To gather safety and efficacy BioRBC data from adult subjects who previously developed transient BioRBC antibody responses by redosing them and observing for adverse clinical or laboratory (i.e., a positive BioRBC antibody titer) outcomes to determine if RBC kinetic study results differ f...
What is the current status of trial NCT02077751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2019-12.
What conditions does trial NCT02077751 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT02077751?
The interventions under investigation include: biotin labelled RBCs (DRUG).
Who is sponsoring clinical trial NCT02077751?
This trial is sponsored by John A Widness, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02077751 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
ACTIVE NOT RECRUITING · Phase 1
-
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
COMPLETED · Phase 1
-
A Phase 1 Study of LY2787106 in Cancer and Anemia
COMPLETED · Phase 1
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.